




Appendix: Supplementary material [posted as supplied by author]  
Part 1: MCE supporting materials and historical context  
 
Tribute to Dr. Ivan Frantz in leading the Minnesota Coronary Experiment team 
 
Reared on Margarine and to the Tune of Spinning Ultracentrifuges: 
A Son’s Recollections of Ivan D. Frantz, Jr. During the Early Days of Lipid Research 
Robert P. Frantz, M.D. 
 
As the youngest son of Ivan and Veronica Frantz, I was born in Minneapolis, MN in 1958 at the 
University of Minnesota Hospitals.  My father spent long days in his laboratory at the Variety Club Heart 
Hospital on East River Road.  In the evening he would sit at the dining room table, a yellow pad in front 
of him, armed with a pencil, an eraser and sharpener, and an array of papers and files.  He hand wrote 
his drafts, and as he did, the entire table would jostle.  He had impeccable cursive, having won awards in 
school for his penmanship.  On weekends he would take me down to the laboratory, pushing back a 
heavy wooden door with his name on it, revealing an exciting world filled with the sound of spinning 
ultracentrifuges.  He showed me the miracle of separating lipid fractions with Percoll gradients, and the 
evolving techniques of electrophoresis.  On crisp autumn Saturdays we would stop in before the 
Minnesota Gopher football game, and if we were lucky he would make a stellar New England clam 
chowder in a beaker over a Bunsen burner.   
 
My father was a brilliant, yet humble man.  His goal was to do the best science possible, and to promote 
public health through efforts to develop sufficient understanding of factors driving cardiovascular disease 
to permit informed intervention.  He did not seek the spotlight.  In the early days of lipid research, 
computers were in their infancy.  As computing evolved and became an important tool for research, he 
taught himself computer languages, including Fortran and Cobol.  He rarely took vacation, and when he 
did always brought along things to work on. 
 
As I reflect on the evolution of thought regarding diet and cardiovascular risk, and having sifted through 
thousands of files from my father’s basement that pertained to his passionate pursuit of lipid research, I 
think about what my father would have thought of the additional analyses so painstakingly conducted by 
Dr. Chris Ramsden and colleagues and reported in the accompanying manuscript. 
 
In the first paragraph of a short paper published in Atherosclerosis in 1977 regarding treatment of 
hyperlipidemia, my father sounded a cautionary note: “Several of the more effective methods of treating 





long as this state of ignorance persists, one must harbor some misgivings that, despite a satisfying fall in 
blood lipid concentrations, the treatment may be doing more harm than good 1.”   In that paper, he closed 
by noting the remarkable Japanese fishermen who had a lifelong diet low in cholesterol and saturated 
fat, and wondering whether that lifelong approach was likely to be greater than what could be achieved 
by dietary modifications later in life.   
 
He performed small crossover studies of the effects of various diets on lipid lowering in healthy college 
students, trying to understand whether the partially hydrogenated soybean oil favored by food 
manufacturers was as effective as corn or unhydrogenated soy oil in lipid lowering.  The partially 
hydrogenated oil did lower cholesterol, but not as much as the other oils, and had less effect on 
triglycerides 2.   
 
The campaign to undertake large clinical trials of dietary modification took many years to come to fruition.  
It was necessary to convince those responsible for public health that such trials were not only worth the 
expense, but also feasible.  Therefore my father undertook preliminary studies to prove feasibility 3.  The 
Minnesota Coronary Survey thus was many years in the making, from its roots in epidemiology of 
cardiovascular disease, to development of analytical techniques capable of measuring lipid levels 
reproducibly, to designing the clinical trials and convincing the necessary policy stewards and funding 
agencies that such trials could and should be carried out.  Completing the MCS was an enormous effort 
on the part of many individuals, including the subjects who agreed to participate.  My father would praise 
the whole team for their efforts in making the work possible.  The entire lipid research team at the U of M 
was passionate about what they were trying to accomplish.  Accordingly the disappointment when the 
overall study results were negative must have been profound.  My father officially had retired from the U 
of M in 1984, though it was hard to see any major difference in his work ethic as an Emeritus Professor 
in the years after that, culminating in the publication of the MCS study results in 1989 when he was 74 
years old.   
 
If he were alive today, I know my father would have been delighted that the data he had devoted his 
career to making possible had been painstakingly revisited in order to shed additional light on the 
frustratingly paradoxical results.  Science is a never ending search for the truth, including the need to 
revise hypotheses, to explain unexpected results, and to apply that knowledge for the betterment of the 









Table A. Full cohort and pre-specified subgroups of the Minnesota Coronary Experiment 
(Sub)groups Key Considerations 
Full cohort With >9,400 participants, the full MCE population was easily the largest randomized controlled diet-heart trial 
testing whether replacement of SFA with vegetable oil rich in LA reduced the risk of CHD and death.  
Women The MCE is the only diet-heart trial to evaluate clinical effects in women after random assignment to either 
serum cholesterol lowering diet or control diet.  Since CHD manifests later in women than men, the 
expanded age range of the MCE population was considered a unique opportunity to assess clinical efficacy 
of the diet in women.  
Men Men were considered a subgroup likely to establish benefit of the serum cholesterol lowering diet, due to 
higher incidence of CHD than women. 
≥ age 65 The MCE is the larger of only two RCTs testing the clinical effects of a serum cholesterol-lowering diet in 
individuals older than 65. Analyses of this high-risk subgroup were planned but not reported. 
< age 65 Participants <65 were considered a population that was likely to see benefit from the serum cholesterol 
lowering diet. 
Primary prevention 
(No EKG evidence of prior myocardial infarction) 
The majority of MCE participants (about 95%) did not have EKG evidence of a current or prior myocardial 
infarction (no pathological Q wave) at randomization. 
Secondary prevention 
(EKG evidence of prior myocardial infarction) 
In the grant proposal, MCE investigators reported that the presence of a pathological Q wave on EKG upon 
entry into the pre-randomization observational phase was associated with an increased risk of a subsequent 
event by a factor of 2.6 4.  Analyses of this high-risk subgroup were planned but not reported. 
Participants consuming study diets for ≥1 year  MCE investigators hypothesized that the effects of the serum cholesterol lowering diet would take substantial 
time to manifest. A special emphasis was placed on participants who were exposed to study diets for ≥ 1 
year, in terms of serum cholesterol measurements, sample size calculations, and subgroup analyses 4-6. 
Autopsy cohort  MCE investigators hypothesized that participants randomized to the serum cholesterol lowering diet would 
have less advanced coronary, aortic and cerebrovascular atherosclerosis and fewer myocardial infarcts and 
strokes at autopsy.   
Table references
4-12






Recovery and validation of MCE data and study materials 
We recovered raw data from the Minnesota Coronary Experiment (MCE) stored on two 9-track 
magnetic tapes (‘tape 2’ and ‘tape 4’) (see fig A below), using similar methods as we previously 
employed to recover missing Sydney Diet Heart Study (see the web appendix of 13). Technical expertise 
in data recovery and conversion was provided by John Svee (Data Conversion Resource, Inc., Aurora, 
Colorado, USA).  Computer Logics software was used to read the raw tape to disk via a pertec interface 
with 9-track equipment attached to Windows 98 boxes in pure DOS mode. Tape 2 contained data written 
to tape on the 327th day of 1988. The raw MCE ‘tape 2’ data was split into 2 logical files with standard 
zero-length separation blocks between files. These data were stored on the tape in fixed length American 
Standard Code for Information Interchange (ASCII) text files. Tape 4 contained data written to tape on 
the 183rd day of 1985. We determined that it was written using Kronos operating system, version 53. This 
Kronos data was found to be expressed in 6-bit, rather than standard 8-bit characters. The data format 
and the exact character conversion table code (Table B-2 on page 106 from 14) were identified and 
translated by trial and error, ultimately resulting in readable ASCII characters which were found to 
represent a related series of punched cards. Each “record” of punched card data ended in a series of “:” 
characters. These were translated from the original varying number of colon characters per line into PC 
record marks (character 13 + character 10). Next these punch card records were programmatically 
assembled into fixed length ASCII text records. This file of 57,664 records was split into three files 
representing Type D sub-records (MCE data collection form 011, see Appendix Section VI.), Type R sub-
records (MCE form 02) and Type X sub-records (MCE forms 02/11).  
In addition to the tape processing, Data Conversion Resource was used to post-process the 
results of numerous scanned data summary tables on green-bar paper. This process took the scanned 
documents translated via OCR and corrected for various OCR errors such as numeral “5” resulting as 
“:S” and so forth.  These fully converted and corrected documents were triple-verified to ensure accuracy 
of character recognition. For further validation, each of the recovered MCE datasets were compared to 
each other and to data reported in the 1989 study publication 8, the 1981 Master’s Thesis 9, and the 1975 
conference proceedings 10-12, as well as numerous other recovered MCE documents and data sources. 
After validation, data elements from all sources were merged into a master file in a format suitable for 
statistical analysis. 
Paper autopsy files were recovered for 149 of the 295 MCE participants who underwent autopsy. 
Each manila autopsy file folder contained completed carbon copies of MCE data forms 08 (Coronary 
Artery Atherosclerosis), 09 (Classification of Myocardial Infarcts), and 10 (Classification of Aorta), but did 
not contain missing data for Atherosclerosis of Brain (Form 12) or Circle of Willis (Form 13).  Recovered 
autopsy data were entered into spreadsheets matching the MCE study forms in a blinded manner, and 
triple-verified for accuracy.  
 
 
We also recovered an extensive collection of FORTRAN cod
Frantz, which outlined the analysis plans
related coding sheets included the original, extensive plans for 
atherosclerosis, aortic atherosclerosis, and cerebrovascular atherosclerosis, arteriosclerosis and infarcts 
according to treatment group, and stratified by gender, age and time on study diets.
We also found evidence that 
(Tape #380, written on 12/12/1974) 
yet been able to recover this tape.
 





 for autopsy materials and other aspects of the study
analyses of myocardial infarcts, coronary 
all autopsy-related data was stored on a 9
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Table B. Intervention start dates and diet duration in the seven MCE hospitals  
Hospital Observational 




Diet start date Diet duration 
(months) 
Willmar 9/1/1966 24 11/6/1968 56 
Hastings 9/1/1966 26 1/14/1969 54 
Fergus Falls 9/1/1966 27 2/11/1969 53 
St. Peter 9/1/1966 31 5/15/1969 49 
Oak Terrace 
Nursing Home 
2/1966  40 6/2/1969 49 
Moose Lake 9/1/1966 37 10/1/1969 45 









Chemical compositions of the intervention and control diets in the seven MCE hospitals 
 
Cal=calories; GMS=grams; %CAL= percentage of food energy; MGMS=milligrams;  CHO= carbohydrates; CHOL=dietary cholesterol; 
POLY=polyunsaturated fatty acids;  SAT=saturated fatty acids; MONO=monounsaturated fatty acids;  TOT FA=total fatty acids; 





Table C: Classification of fatal and non-fatal events in the MCE 
Event code Diagnostic category 
01 Acute myocardial infarction, autopsied 
02 Acute myocardial infarction, not autopsied 
03 Sudden cardiac death (cardiac arrest) 
04 CHD death (other) 
05 Acute myocardial infarction, non-fatal 
06 Acute stroke, non-fatal 
07 Acute CHD illness, non-fatal 
08 Silent myocardial infarction (EKG only) 
09 All other deaths 
10 Stroke, fatal 
 
Ascertainment and coding of fatal and non-fatal events  
Fatal and non-fatal events were assigned specific International classification of diseases codes 5 by the 
PI under masked conditions based on evaluation of hospital chart and autopsy findings and, when 
necessary, consultation with the attending physician. Each event was later assigned to one of ten 
categories of MCE coded events (table C). To ensure masking was not compromised by the anticipated 
between-group differences in follow-up serum cholesterol, the PI did not have access to serum 
cholesterol measures 7.  
 
The MCE team also paid close attention to the overall death rate in both groups since “atherosclerosis 
may contribute to many deaths in which no actual fresh myocardial infarct or coronary occlusion has 
occurred” 7, and “deaths attributed to pneumonia or other causes could be related ultimately to coronary 

















Table  D: Important MCE data that remain missing 
Unanswered Questions MCE Hypotheses Data reported Missing data Why these data are important 
     Full cohort and pre-specified subpopulations 
 
Did the serum cholesterol lowering diet 
alter risk for CHD events and deaths in 
patients with pre-existing CHD 
(secondary prevention)? 
The diet is likely to be 
protective in this high-
risk population  
392 randomized 
subjects had a 
pathological Q wave 
on initial EKG  
CVD events and deaths 
were not reported for this 
high-risk population 
This MCE subgroup is the second largest secondary 
prevention RCT cohort with provision of LA-rich vegetable 
oil in place of SFA (without co-provision of EPA+DHA).  
The Sydney Diet Heart Study (n=458) is the largest such 
cohort. 
Did the serum cholesterol lowering diet 
alter risk for CHD events and deaths in 
participants 65 years of age and 
older? 
Effects in older adults 
are unknown. “Even a 
clear negative result in 
older subjects would 








increased risk of 
death  
(without statistics). 
CVD events were not 
reported. It is not clear if the 
increased risk of death in 
treatment group was 
statistically significant. 
The MCE is the larger of only two RCT to test whether 
replacing SFA with vegetable oil rich in LA alters the risk of 
CHD and death in older adults. 
     Associations between changes in serum cholesterol and CVD events and deaths 
 
Was the degree of serum cholesterol 
lowering related to risk of CHD events 
and CHD deaths? 
The degree of serum 
cholesterol lowering is 
likely to be inversely 
associated with risk of 
CHD events 
No data reported. We 
recovered all serum 
cholesterol data. 
CHD and CVD events for all 
subjects with serum 
cholesterol data 
The MCE is the largest RCT to test whether the serum 
cholesterol lowering effects of replacing SFA with 
vegetable oil rich in LA alters the risk of CHD. 
     Post-mortem analyses 
 
Did the serum cholesterol-lowering 
diet reduce the progression of 
atherosclerosis in the Circle of Willis 
(brain) or the risk of stroke? 
The diet is likely to 
reduce strokes and 
atherosclerotic 
progression  
No data reported 
Postmortem cerebrovascular 
atherosclerosis and infarct 
data for all 295 autopsies 
(Tape #380, 12/12/1974) 
Only postmortem human data looking at the role of diet-
induced serum cholesterol lowering, or of increasing LA in 
place of SFA, on cerebral atherosclerosis or ischemic 
stroke. 
Did the serum cholesterol-lowering 
diet reduce the progression of aortic or 
coronary atherosclerosis or myocardial 
infarction? 









infarct data for 149 
subjects  
Postmortem coronary, aortic 
atherosclerosis and 
myocardial infarct data for 
146 of 295 completed 
autopsies (MCE Tape #380) 
Only postmortem human data looking at the role of diet-
induced cholesterol lowering, or of increasing LA in place 
of SFA, on aortic or coronary atherosclerosis or myocardial 
infarcts (MI). Analysis of recovered data (partial dataset) 
found more MI, and a signal toward increased coronary 
atherosclerosis in the cholesterol lowering diet group. 
     New hypotheses to explain unfavorable study results 
 
Did the serum cholesterol-lowering 
diet have adverse effects in 
subpopulations known to have 
increased linoleic acid oxidation  
(eg, alcoholics, heavy smokers, older 
adults)? 
Hypothesis proposed 
to help explain 
unfavorable results of 




No data reported 
Smoking status, alcoholic 
diagnosis and other 
diagnostic coding 
In the Sydney Diet Heart Study, there was significant effect 
modification by drinking status; heavy drinkers (HR 2.89; 
p=0.03) and smokers (HR 2.09; p=0.03) who were 







Table E: Serum cholesterol lowering according to diet adherence in the MCE 
 
Data are from the ≥1 year serum cholesterol cohort.  Values are for average change in serum cholesterol from baseline.  
Meals 
attended 
Intervention Control Combined groups 
n mean sd n mean sd n mean sd 
>98% 390 -18.0 10.7 379 -2.8 13.6 769 -10.5 14.4 
>90-98% 433 -14.3 12.8 451 -1.0 14.7 884 -7.5 15.3 
>70-90% 258 -10.7 12.5 238 0.6 15.8 496 -5.2 15.3 
≤70% 98 -2.9 15.4 108 1.6 13.3 206 -0.6 14.5 






Table F: Characteristics of the MCE autopsy cohort (n=149) 
  Intervention Control t-Test  
p-value   Mean (SD) n Mean (SD) n 
Age at randomization, years 71.1 (11.9) 76 67.8 (14.1) 73 0.127 
Systolic blood pressure, mmHg 127 (22.9) 75 128 (19.8) 68 0.829 
Diastolic blood pressure, mmHg 77 (13.4) 75 75.1 (11.5) 68 0.363 
Serum Cholesterol, mg/dL 214 (50) 69 206 (65) 62 0.403 
Serum Triglycerides, mg/dL 109 (39.7) 69 113 (70.5) 62 0.699 
BMI 23.6 (4.5) 69 23.2 (3.6) 61 0.617 
Diet exposure in days 345 (272) 76 352 (312) 73 0.886 
% Missed meals† 3.4 (5.4) 69 3.7 (7.0) 62 0.788 
% Male 60.5 (49.2) 76 68.5 (46.8) 73 0.313 







Table G: Association between serum cholesterol and risk of infarct and atherosclerosis in the MCE autopsy cohort 
 
  Intervention   Control   Both Groups 
 
n Coef† 95% CI 
p-
value 
n Coef† 95% CI 
p-
value 
n Coef† 95% CI p-value 
Coronary 
atherosclerosis score 
64 -1.75 (-3.88, 0.38) 0.09 
 




61 0.10 (-0.23, 0.43) 0.49   56 -0.12 (-0.49, 0.26) 0.47   117 -0.02 (-0.33, 0.28) 0.85 
      
  n OR‡ 95% CI 
p-
value 
n OR‡ 95% CI 
p-
value 
n OR‡ 95% CI p-value 
Myocardial infarcts 65 0.98 (0.56, 1.72) 0.96   59 1.02 (0.52, 1.99) 0.95   124 1.19 (0.84, 1.69)  0.34 
 
†Coefficients are change in atherosclerosis score for each 30 mg/dL decrease in average serum cholesterol. Based on linear regressions for atherosclerosis score as a 
function of average follow-up serum cholesterol, adjusted for baseline serum cholesterol, age, BMI, gender, adherence to the diet, and systolic blood pressure, and clustering 
within hospital. 
‡ Odds ratio for each 30 mg/dL decrease in average serum cholesterol. Based on logistic regressions for having at least one infarct as a function of average follow-up serum 





Fig B: Ecological association between 
States in the 20th century 
Ecological associations between LA
Notable confounders in the 1909-1960 interval include diagnostic bias due to increasing availability of 
electrocardiograms, increased health care
coronary heart disease. Notable confounders in the 196
(eg, major declines in smoking & secondhand smoke exposure, widespread
ambulances), and major advances 
treatments (e.g., coronary artery bypass graft, angioplasty).
†Mean annual LA intakes are estimated from USDA economic disap
percentage of food energy 15; ‡CHD mortality data downloaded from 
Abbreviations: CHD, coronary heart disease; LA, linoleic acid; 
 
 
Ecological associations between LA intake and CHD mortality have been cited as supp
the diet-heart hypothesis17. However, these associations are subject to many important 
confounders and wholly dependent on the timeframe selected (
rise in per capita LA intake between 1909 
steep rise in CHD mortality. By contrast, the comparatively modest inc
between 1960 and 2000 coincided with a steep decline in CHD mortality. Drawing a causal 
inference from this latter interval requires disregarding both the rise in CHD, and many potential 
dominant confounders (see legend of 
per capita LA intake in the United States occurred before 1961, when serum cholester
lowering dietary advice was initiated.
change in LA and CHD mortalit
 and CHD mortality are subject to many important confounders. 
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Table H: Linoleic acid contents of nuts, seeds, and vegetable oils  




Corn Oil 53.5 
Soybeans 10.8 
Soybean Oil 51.0 
Sunflower Seeds 23.1 
Sunflower Oil† 65.7 
Cottonseed Oil 51.5 
Canola Oil 19.0 
Almonds 12.3 
Pecans 20.6 
LA, linoleic acid. Fatty acid contents of oils vary to some extent by season, latitude, and other conditions. USDA 
National Nutrient Database numbers: corn 11167, corn oil 04518, soybeans 16111, soybean oil 04044, sunflower 
seeds 12036, sunflower oil 04506, cottonseed oil 04502, canola oil 04582, almonds 12061, pecans 
12142
18








Systematic review & meta-analysis of RCTs that replaced SFA with LA rich vegetable oil  
 
Effects of Replacing Saturated Fat with Vegetable Oils Rich in Linoleic Acid on Coronary Heart 




A key component of dietary guidelines has long been to replace saturated fat (SFA) with vegetable oils 
(e.g., corn oil, safflower oil, soybean oil) that are rich in linoleic acid (LA). This advice is based on the 
traditional diet-heart hypothesis prediction that replacement of SFA with LA decreases coronary heart 
disease (CHD) and all-cause mortality by reducing serum LDL and total cholesterol. 
Objective 
To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that 
specifically tested whether replacement of SFA with LA-rich vegetable oil decreases CHD mortality and 
all-cause mortality. 
Methods 
Studies published in English from 1950 to Sept. 2015 were identified through systematic searches of 
PubMed, EMBASE, and CINAHL, hand-searching of related publications, grey literature sources, and 
contact with study investigators and family members of deceased investigators to identify potentially 
unpublished trials and endpoints. Studies were included if they randomly assigned individual participants 
to a diet intervention that provided vegetable oil rich in linoleic acid in place of saturated fat compared to 
a usual care control diet, reported deaths from CHD or all-causes, and were not confounded by unequal 
intensity of major concomitant dietary or medical interventions. Study quality and bias assessment 
included the following:  random sequence generation; adequacy of allocation concealment; adequacy of 
blinding of participants and personnel; adequacy of blinding of outcome assessments; selective 
reporting; systematic differences in between-group care; and study-specific sources of potential bias. All 
review stages were conducted independently by two investigators. Pooled hazard ratios (HR) were 
calculated using inverse-variance weighted random-effects meta-analysis. 
Results 
Of 1270 publications initially identified, only five RCTs were included in the main analysis representing 
10,808 participants, 324 deaths attributed to CHD, and 1,001 deaths from all-causes.  The mean change 
in serum cholesterol in the course of these trials ranged from 7.8 to 13.8% lower in the intervention vs. 
control groups. In meta-analyses, these cholesterol-lowering interventions showed no evidence of benefit 
on CHD mortality (HR 1.13; 95% CI 0.83, 1.54) or all-cause mortality (HR 1.07; 95% CI 0.90, 
1.27).  There was evidence of statistical heterogeneity in both magnitude and direction of effect for the 
CHD mortality (I2:  45.1%; Tau2:  0.0534) and all-cause mortality (I2: 38.8%; Tau2: 0.0132). In sensitivity 
analyses including additional 3 RCTs that were confounded by provision of n-3 EPA+DHA and other 
major diet changes, and/or relied on advice only (with modest diet changes) null results were noted for 
both CHD mortality (HR 1.00; 95% CI 0.81, 1.24; I2:  37.5%;) and all-cause mortality (HR 1.00; 95% CI 
0.87, 1.15; I2:  34%).  Reasons for heterogeneity of the pooled HR among the eight studies were 







Available RCT evidence demonstrates that replacement of SFA with LA-rich vegetable oil effectively 
lowers serum cholesterol, but does not support the hypothesis that this translates to lower risk of death 
from CHD or all-causes. 
 
INTRODUCTION  
The traditional diet-heart hypothesis predicts that replacing dietary SFA with vegetable oils rich in LA will 
reduce CHD events and deaths by lowering serum cholesterol. Advice to replace SFA with LA-rich 
vegetable oils (e.g., corn oil, sunflower oil, safflower oil, cottonseed oil, or soybean oil) has been a 
cornerstone of dietary guidelines for the past half-century (see main paper, Figure 10). However, the 
lack of supporting RCT evidence for such advice has been a source of controversy.13, 19 Several diet-
heart meta-analyses have been published, but they have not specifically examined the effects of 
replacing SFA with LA-rich vegetable oils. For example, a meta-analysis by Hooper et al 20 included 
RCTs that lowered SFA but did not distinguish between trials that replaced SFA with LA-rich oils, from 
those that replaced total and saturated fat with carbohydrates, and also included RCTs that markedly 
increased dietary EPA+DHA alongside LA. Similarly, Mozaffarian et al 21 included RCTs that markedly 
increased dietary EPA+DHA from seafood and cod liver oil, among other diet changes (e.g. sugar 
restriction, increase in fiber).  EPA and DHA are not present in vegetable oils and are reported to 
influence CHD pathogenesis by mechanisms independent of cholesterol lowering. Therefore, it is not 
clear whether the results of previous meta-analyses are driven by 1) reductions in SFA, 2) replacement 
of SFA with LA-rich vegetable oil, 3) or to increases in EPA+DHA.  The objective of this systematic 
review and meta-analysis is to determine whether RCTs that specifically replaced SFA with LA-rich 
vegetable oil(s) provide evidence to support the traditional diet-heart hypothesis. 
METHODS 
We followed the PRISMA (www.prisma-statement/org) guidelines22 throughout the design, 
implementation, analysis, and reporting of this systematic review and meta-analysis. 
 
Data sources 
A protocol for this systematic review and meta-analysis has not been registered. A search was 
conducted using three major databases:  the National Library of Medicine’s PubMed, EMBASE, and 
CINAHL.  We used search terms utilized by other investigators (2010) (table I).21 Published meta-
analyses and reviews were examined for additional peer-reviewed articles not discovered through 
database searches.19-21 The search strategy focused on retrieval of articles from the peer-reviewed 
medical literature, reference lists of systematic reviews, meta-analyses, individual trials, grey literature 
sources, and, based on our previous work, also included extensive contact with study investigators and 





Table I.  PubMed Search Terms, 25 September 2015 
 
("Fatty Acids, Omega-6"[Mesh] OR "unsaturated fatty acid"[tiab] OR "unsaturated fatty acids"[tiab] OR "unsaturated 
fat"[tiab] OR "unsaturated fats"[tiab] OR "polyunsaturated fatty acid"[tiab] OR "polyunsaturated fatty acids"[tiab] OR 
"polyunsaturated fat"[tiab] OR "polyunsaturated fats"[tiab] OR "omega-6"[tiab] OR "linoleic"[tiab] OR "octadecadienoic 
acid"[tiab] OR "safflower oil"[tiab] OR "sesame oil"[tiab] OR "soybean oil"[tiab] OR "soyabean oil"[tiab] OR "corn oil"[tiab]) 
AND ("cardiovascular diseases"[Mesh] OR "cardiovascular disease"[tiab] OR "cardiovascular diseases"[tiab] OR "heart 
disease"[tiab] OR "heart diseases"[tiab] OR "myocardial infarction"[tiab] OR "myocardial infarctions"[tiab] OR "heart 
attack"[tiab] OR "heart attacks"[tiab] OR "sudden death"[tiab] OR "sudden deaths"[tiab] OR "coronary syndrome"[tiab]) NOT 
("Case Reports"[Publication Type] OR "stroke"[tiab] OR "strokes"[tiab] OR "cerebrovascular accident"[tiab] OR 
"cerebrovascular accidents"[tiab] OR "Fatty Acids, Omega-3"[Mesh] OR "omega-3"[tw] OR "n-3"[tw]) AND ((Clinical 




Study selection and data extraction 
Included in the main analysis were all serum cholesterol-lowering RCTs with a publication in English that 
(a) randomly assigned individual participants, (b) provided an LA-rich vegetable oil intervention in place 
of SFA, compared to a usual care control diet, (c) were not confounded by the addition of large quantities 
of n-3 EPA and DHA or by other major concomitant interventions (e.g., complex diet pattern changes) or 
unequal intensity of medical management (e.g., smoking cessation advice or blood pressure control), 
and (d) reported deaths due to CHD or all causes. Hence, RCTs that provided large quantities of n-3 
EPA and DHA, or provided advice only without provision of LA rich oils were excluded from the main 
analysis, as were studies with only biochemical or intermediate endpoints. Sensitivity analyses included 
diet-heart RCTs that also provided large quantities of n-3 EPA and DHA or provided advice only without 
provision of an LA-rich study oil, but otherwise met the inclusion and exclusion criteria for the main 
analysis. 
 
All review stages were conducted independently by two investigators. Studies were screened based on 
an inspection of their titles and/or abstracts.  Methods papers were carefully examined to determine key 
elements of the dietary interventions. Duplicate publications and abstracts from the same study were 
reviewed to examine consistency and to glean additional information about design and study outcomes 
but were otherwise not considered. Reviews and commentaries were not considered. Studies with a 
primary focus on medication evaluation were also excluded.   
 
Data extracted from the studies included the number of trial participants in the experimental and control 
diets as well as deaths from coronary heart disease (CHD) and all causes by intervention group.  Also 
extracted were hazard ratios where available along with the maximum follow-up time for each study.  





diets.  The change in total cholesterol by group assignment was calculated for each study. Also noted 
was whether the sample populations were institutionalized or free living and whether the study target was 
secondary prevention of CHD (e.g., population recruited from post-infarction population) or a population 
with and without CHD at baseline.   
 
Bias Assessment  
Risk of bias was assessed for individual studies and included the following study characteristics: 1) 
random sequence generation; 2) allocation concealment; 3) blinding of participants and personnel; 4) 
blinding of outcome assessments; 5) selective reporting; 6) systematic differences in between-group 
medical care; and 7) study-specific sources of potential bias.  Two investigators rated the risk of bias 
independently and resolved any discrepancies with discussion.   
Statistical Analysis 
We calculated pooled risk estimates (hazard ratios with 95% confidence intervals and p-values) for CHD 
death and all-cause mortality for the five RCTs that met inclusion criteria (main analysis) and again 
including Oslo Diet Heart Study, the St. Thomas Atherosclerosis Regression Study, and the Diet and Re-
infarction Trial in sensitivity analysis. When hazard ratios were not available, they were estimated by 
calculating risk ratios.  Results of random effects models are reported using the Dersimonian and Laird 
inverse-variance weighting method 23 . Between-study heterogeneity was assessed with the I2 statistic 
along with an estimate of between-study variance (Tau-squared) and stratification by study oil.  
Publication bias was assessed by visual inspection of a funnel plot of the treatment effect versus 
standard error. Because there was some evidence of imbalance in the funnel plot, in a sensitivity 
analyses, estimates were examined using a trim and fill procedure and excluding the small Rose Corn 
Oil Trial.  Potential sources of heterogeneity were explored using stratified fixed effects meta-analysis 
(for type of PUFAs) and inverse variance weighted meta-regressions (for between-group cholesterol 
reduction and increases in dietary linoleic acid). 
 
Statistical analyses were performed using Stata version 13.1 (Stata Corporation, College Station, TX, 







The searches returned a total of 1260 articles, 301 of which were duplicate articles or additional articles 
on the same study (fig C 3).  Ten additional articles were identified through review articles. Most 
screened studies were excluded because they were supplement-only studies, they were drug 
interventions, or they only reported biochemical endpoints. Others were observational studies, 
commentaries, genetic studies, trial design studies, studies to develop dietary measures, or compliance 
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Table J.  Characteristics of the 60 excluded dietary intervention studies 
First author or Study Name, 
primary aim 
Dietary interventions Concomitant 
interventions 
Mortality outcome   




Effects of diets on mortality 
Participants were not randomized. 
Crossover study of two hospitals (one 
control, one intervention) (see p. 47) 
Higher exposure to 
cardiotoxic drug 
thioridazine in control  
CHD mortality 
 
2.      Lyon Diet Heart Study 
27-29
 
Secondary prevention of CHD death 
Multiple between-group differences in 
diet 
Did not substitute LA-rich oil in place of 
SFA 
 







Secondary prevention of CHD 
events and death 
Multiple between-group differences in 
diet 
 
Did not substitute LA-rich oil in place of 
SFA 
 
No between-group  
imbalance 
Composite outcome: 
all-cause + CHD 







Secondary prevention of CHD 
events and death 
Multiple between-group differences in 
diet 
 
Did not substitute LA-rich oil in place of 
SFA 
 
No between-group  
imbalance  





5. Indian Diet Heart Study
32
 
Secondary prevention of CHD 
events and death 
Multiple between-group differences in 
diet 
 
No between-group  
imbalance 
Fatal and non-fatal MI, 
SCD 




Secondary prevention of CHD 
events and death 
Multiple between-group differences in 
diet 
Did not substitute LA-rich oil in place of 
SFA 






Effects of diet on cerebral blood 
flow 
Multiple between-group differences in 
diet 










Effects of diets on blood pressure 
Multiple between-group differences in 
diet 
 







In metabolic syndrome, effects  of 
diet on endothelial function and 
inflammatory markers 
Multiple between-group differences in 
diet 
 
Did not substitute LA-rich oil in place of 
SFA 
 







In metabolic syndrome, effect on 
body composition and oxidative 
stress 
Multiple between-group differences in 
diet 
 







Effects of diets on gene expression 
Multiple between-group differences in 
diet 








First author or Study Name, 
primary aim 
Dietary interventions Concomitant 
interventions 




Effects of diets on CHD risk factors 
in metabolic syndrome 
High vs. low CHO diet 







Effects of diets on CHD risk factors 
in hypercholesterolemia 






Effects of diets on CHD risk factors 
High vs. low SFA: CHO vs. beef  






Effects of diets on lipid profile in 
hypercholesterolemia 
SFA replaced with MUFA & mixed n-3/n-6 
PUFA 






Effects of diets on lipid oxidation in 
hypercholesterolemia 
Canola vs. olive. vs. sunflower oil feeding 






Effects of diets on CHD risk markers 
in older adults 
ALA vs. EPA/DHA rich diet 







Effects of diets on CHD risk factors 
in Type 2 diabetics 
Multiple between-group differences in 
diet 
 






Effects of diets on lipid metabolites 
in postmenopausal women 
High fat vs. low fat diet 






Effects of diets on CHD risk factors 
High/low LA+/- high/low n-3 diets 
Did not substitute LA-rich oil alone in 





Effects of diets on lipid profile in 
hypercholesterolemia  
Fatty fish substituted for 
pork/chicken/beef 






Effects of diets on lipid profile in 
Type 2 diabetes 
LA-rich vs. Oleic acid-rich diet 






Effects of diets on lipids and insulin 
in Asian Indians 
Moderate vs. high n-6:n-3 PUFA diet 






Effects of dietary oils on CHD risk 
factors in hypertensive men 
Oleic vs. LA-rich vs. ALA-rich oils  
















Effects of diets on blood pressure 
Two levels of increased PUFA substituted 
for SFA 
None None 
26. TRANSLinE Study 
60-62
 
Effect of diets on CHD risk factors 
High vs. low TFA 






Effect of diets on cytokines and 
cellular immune markers 
SFA vs. TFA vs. Soy oil None None 




Stearic acid, oleic acid feeding studies 






Effects of diets on CHD risk factors 
TFA vs. n-3 PUFA 






Effects of diets on lipids/hemostasis 




Effects of diets on insulin sensitivity 
and CHD risk factors 
Multiple between-group differences in 
diet 
 







Effects of diets on lipids 




Effects of diets on lipids 
Lean vs. fatty fish vs. meats 






Effects of diets on endothelial 
function 
Fish vs. control diet 






Effects of diet on CHD biomarkers 
Fish vs. control diet 






Effects of diets on serum lipids 
MUFA vs. control 






Effect of diets on adiponectin  
High vs low SFA:UFA diet 






Effects of diets on CVD risk factors 
High vs. low CHO in calorie restricted diets 






Effects of diets on CHD risk factors 
in metabolic syndrome 
High vs. low CHO in calorie restricted diets 







First author or Study Name, 
primary aim 
Dietary interventions Concomitant 
interventions 




Effects of diets on CHD risk factors 
CLA vs. Control fat 






Effects of diets on CVD risk factors 
Mixed FA and CHO dietary changes 






Effects of diets in metabolic 
syndrome 
Hi MUFA vs. SFA vs. CHO 






Effects of diets on CVD risk factors 
MUFA vs. SFA 






Effects of diets on vascular 
inflammation in 
hypercholesterolemia 
ALA vs. LA vs. SFA diets 






Effects of diets on NAFLD 
Olive or canola oil substituted for usual 





Effects of diets on insulin sensitivity 
4 diets altering n-6:n-3 ratios 






Effects of diets on lipids 
Partially hydrogenated soybean, corn, 
sunflower oils; Did not substitute LA-rich 





Effects of diets on CHD risk markers 
in metabolic syndrome 
n-3 +/- polyphenols vs. control  







Effects of diets on CHD risk markers 
TFA vs. SFA 
 







Effects of diets on CHD risk markers 
MUFA VS. SFA 
 







Effects of diets on lipids 
MUFA vs. PUFA vs. SFA None None 
52. SYSDIMET
100
 (de Mello) 
Effects of diets on endothelial 
function in metabolic syndrome 






Effects of diets on endothelial 
function 
SFA vs. MUFA vs. n-6+n-3 PUFA 






Effects of diets on endothelial 
function 
SFA vs. Mediterranean vs. low TF/SFA diet 







First author or Study Name, 
primary aim 
Dietary interventions Concomitant 
interventions 





Effects of fish consumption on 
lipids in metabolic syndrome 
White fish vs. no fish 
 







Effects of LA vs. SFA margarine on 
diabetic micro- & macro-
angiopathy 
Linoleic acid-rich intervention vs. 
‘saturated margarine’ intervention (35%E 
as SFA). 
Comparison group with unrealistic 
amount of SFA (35%E) exclusively from 







Secondary prevention of CHD 
mortality 
Linseed oil (ALA) vs corn oil (LA) in place of 
other oils ; no SFA control group 
None CHD and all-cause 





Effects of diets on lipids/insulin in 
healthy males 
Low fat, high carbohydrate diet vs. high 
oleic sunflower oil (MUFA) 
 








Effects of diets on inflammatory 
markers 
Partially hydrogenated soybean oil vs. 
high oleic palm oil vs. palm stearin 
 







Effect of diets on DM 
markers/lipids among diabetics 
SFA vs. MUFA vs TFA (trans MUFA) 
 




Abbreviations:  ALA = alpha linolenic acid; CABG/PCI = coronary artery bypass surgery/percutaneous coronary intervention; CHD = coronary heart disease; 
CHO = carbohydrate; LA = linoleic acid; MI = myocardial infarction; MUFA = mono-unsaturated fatty acid; PUFA = poly-unsaturated fatty acid; SCD = 
sudden cardiac death; SFA = saturated fatty acid; TF = total fat; TFA = trans fatty acid.  
 
RCTs included in the main analysis  
Only five RCTs met our inclusion criteria: the Minnesota Coronary Experiment (MCE) 8-12, 109, the Sydney 
Diet Heart Study (SDHS) 13, 110-113, the Rose Corn Oil Trial (RCOT) 114, the Los Angeles Veterans study 
(LA Vet) 115-122, and the Medical Research Council Soy study (MRC Soy) 123, 124 (table K).  These are the 
five known RCTs that randomly assigned individual participants to a diet intervention that provided 
vegetable oil rich in linoleic acid in place of saturated fat compared to a usual care control diet, reported 
deaths from CHD or all-causes, and had no between-group differences in major concomitant 
interventions.  Compared to control groups, all five intervention groups lowered serum cholesterol (mean 
range from 8 to 14% lower). They represent a total of 10,808 individuals (5,413 in the intervention diet 
groups and 5,395 in the control diet group), 324 CHD deaths (169 intervention, 155 control), and 1,001 






RCTs included in sensitivity analyses 
Three additional RCTs were included in a sensitivity analysis: the Oslo Diet Heart Study (ODHS), the St. 
Thomas Atherosclerosis Regression Study (STARS), and the Diet and Re-infarction Trial (DART) (table 
K). These diet-heart trials, which randomly assigned individual participants and reported CHD deaths 
and all-cause mortality, have been included in previous meta-analyses on this topic. However, two of 
these trials were confounded by unequal application of other dietary factors, and another achieved only a 
very modest change in dietary LA without provision of study oils.   
 
ODHS 
The ODHS has often been represented as a test of the replacement of SFA with an LA-rich vegetable oil 
(soybean oil). However, in addition to soybean oil, the intervention group received a very large dose (≈5 
grams per day) of n-3 EPA+DHA from provision of sardines canned in cod liver oil, and was advised to 
restrict sugar intake and to replace refined carbohydrates with less processed selections 125-127.  Since 
EPA+DHA (and sugar) are reported to influence CHD risk by mechanisms independent of serum 
cholesterol lowering, it is not possible to determine which intervention components were responsible for 
study results.  
 
STARS 
STARS 128-130 has often been represented as a test of the replacement of SFA with an LA-rich vegetable 
oil. However, unequal administration of multiple dietary factors do not allow for determination of the 
effects of LA. For example, the STARS intervention group received advice (and some study foods) to: (1) 
reduce total fat and SFA; (2) increase n-6 and n-3 polyunsaturated fatty acids, (3) avoid processed 128 
foods, and (4) increase dietary fiber (especially the soluble fiber polygalacturonate) 129. While this 
intervention had only a very modest (non-statistically significant) increase in n-6 LA (+1.6%E) 128, it 
doubled EPA+DHA from (100 to 210 mg per day), lowered total fat by 27%, and increased fiber by 53%. 
Given these multifaceted changes, the very modest increase in LA likely accounted for only a small 
fraction of the observed 12.2% serum cholesterol lowering achieved. Taken together, this study design 
provides little insight into whether replacement of SFA with LA rich vegetable oils can reduce CHD and 
death. Nevertheless, since other meta-analyses on this topic included STARS, we include it here in 
sensitivity analysis.  
 
DART 
The DART ‘fat advice’ intervention group achieved only a very modest reduction in serum cholesterol  
(-4%), and only modestly increased total polyunsaturated fatty acids, without providing study oils or 
reporting the specific n-6 and n-3 content of such increases. Given these limitations, it is not clear how 





reduces risk of CHD and death (the traditional diet heart hypothesis) 131-136. Nevertheless, since other 
meta-analyses on this topic included DART, we include it here a sensitivity analysis. 
 
The eight RCTs in the sensitivity analysis represent a total of 13,328 individuals (6664 in each diet 
group) with a total of 609 CHD deaths (304 in the treatment, 305 in the control group) and 1,315 deaths 
from all causes (668 treatment, 657 control). 
 
 
Exclusion of the Finnish Mental Hospital Study (FMHS) 
The FMHS has been included in some previous meta-analyses of RCTs 21. However, the FMHS is not 
suitable for inclusion because patients were assigned by hospital and were not randomized as individual 
patients, among other critical limitations (Reviewed in 109, 137). For example, there was disproportionate 
exposure to the cardiotoxic drug thioridazine in one (control) study arm. The FMHS was a 12-year 
crossover study that assigned two hospitals (Hospital N and Hospital K) of mostly schizophrenic patients 
(77% in K and 69% in N) in 1959 to either a soybean oil based serum cholesterol-lowering diet (N) or the 
usual hospital diet (K) for 6 years. After this initial 6-year phase, diets were switched so that Hospital N 
patients received the Hospital N usual diet and Hospital K patients received a soybean oil diet. Issues 
related to within-hospital diet exposures at crossover in 1965 also confounded this unusual design. For 
example, study populations were ‘rejuvenated by discarding the six oldest annual cohorts and admitting 








All studies included in both the main and sensitivity analyses were parallel-group randomized controlled 
trials with blinded outcome assessment and no apparent systematic between-group differences in 
medical care (tables K and L). The possibility of selective reporting has been documented for both the 
SDHS13 and, in this report, the MCE. Potential sources of bias in the five RCTs included the main 
analysis are summarized in tables K and L.  
 In the MCE and SDHS, the intervention groups replaced major sources of SFA (e.g. animal fats, 
common hard margarines, shortenings) with both LA-rich vegetable oils and polyunsaturated soft 
margarines. Since polyunsaturated margarines contain some trans fatty acids (TFA), it has been 
speculated that the unfavorable results of these trials could be due to TFA 
(http://www.bmj.com/content/346/bmj.e8707/rr/629609). However, upon careful examination of the 
intervention diets and the control diets in these RCTs, it becomes clear that between-group differences in 
TFA are an exceedingly unlikely explanation for these unfavorable findings (reviewed in 
http://www.bmj.com/content/346/bmj.e8707/rr/631590). For example, the liquid vegetable oils and 
polyunsaturated margarines provided to the intervention groups displaced substantial amounts of 
common hard margarines, shortenings and other TFA-rich foods that were present in the control diets 
(see Limitations section in the main paper). 
 The RCOT was small (n=84), and we only used two of the three randomized groups (corn oil 
group (n=28) and control diet group (n=26)).  
The baseline and control diets in the LA Veterans Study were rich in hydrogenated oils 121 and 
contained ≤0.1%E α-linolenic acid (ALA). This extraordinarily low (deficient?) level of ALA is rare in 
modern diets and is unlikely to be achieved without extensive hydrogenation. Since the intervention 
increased n-3 ALA to more normative levels (0.7%E), the results of this study may be confounded by one 
group experiencing recovery from a deficient state.   






Table K. Characteristics of randomized controlled trials that replaced SFA with LA-rich vegetable oil(s)  
 






















Studies included in primary analysis†    





Institutionalized Men & 
Women with and 
without CHD 
Intervention 61 269 4541 
Yes No -13.8% ≤ 4.5 years 
Control 54 248 4516 





Ambulatory Men with 
CHD 
 
Intervention 36 39 221 
Yes No -7.8% ≤ 7 years 
Control 24 28 237 
          
Rose Corn Oil 
114
 
Ambulatory Men with 
CHD 
 
Intervention 5 5 28 
Yes No -11.8% ≤ 2 years 
Control 1 1 26 






with and without CHD 
Intervention 42 174 424 
Yes No -12.7% ≤ 8 years 
Control 51 178 422 





Ambulatory Men with  
CHD 
Intervention 25 28 199 
Yes No -13.3% ≤ 7 years 
Control 25 31 194 
Studies included in sensitivity analysis only    




Ambulatory Men with  
CHD 




-13.9% ≤ 5 years 
Control 50 55 206 





Ambulatory Men with  
CHD 




from 100 to 
210 mg/day) 
-12.2% ≤ 3 years 
Control 3 3 28 
          
Diet and Re-infarction 
Trial 
131-136 
Ambulatory Men with  
CHD 
Intervention 35 111 1018 
No No -4% ≤ 2 years 
Control 47 113 1015 
†The Finnish Mental Hospital Study (FMHS) has been included in some previous meta-analyses of RCT 21. However, the FMHS is not suitable for inclusion because patients were assigned by hospital and not 
randomized as individual patients, and the cardiotoxic medication thioridazine was used disproportionately in one study arm 13, 109. ‡Reports the between-group difference in the change in cholesterol over the 




















Other potential bias Increased 
dietary LA? 
Concurrent 







Studies included in main analysis 
MCE 8-12, 
109 
Low Low Double-blind Moderate ‡ Low Low Yes  
(+8.5%E) 




Low Low Blinded 
outcome 
assessment 
Moderate ‡ Low Low Yes  
(+7.1%E) 




Low Low Blinded 
outcome 
assessment 








Low Low Double-blind Low Low Control diet high in 
hydrogenated oils and n-3 
deficient  









Low Low Blinded 
outcome 
assessment 






Studies included in sensitivity analysis only 
ODHS 
125-127 
Low Low Blinded 
outcome 
assessment 
Low Low Treatment group reduced 
sugar, low quality 
carbohydrates. Control 
diet very high in partially 
hydrogenated fish oil.  
Yes 
(+12.3%E) 
Yes¶ (+≈5g/d of 






Low Low Blinded 
outcome 
assessment 
Low Low Small trial with 3 study 
groups. Run-in phase with 
cholestyramine.  













Low Low Blinded 
outcome 
assessment 





Unknown Very modest  
(-4%) ǁ 
‘Low’ refers to low risk of bias, ‘moderate’ refers to moderate risk of bias 
‡ Recovered data included in 2013 and 2015 publications ¶ Massive dose of EPA+DHA due to provision of sardines canned in cod liver oil;  
§ STARS had very modest increase LA (+1.6%E), which is predicted to account for only a very small amount of serum cholesterol lowering that was achieved.  
ǁ DART had modest increase in total PUFA (+2.8%E) and modest reduction in serum cholesterol (-4%). 
Abbreviations: MCE, Minnesota Coronary Experiment; SDHS, Sydney Diet Heart Study; RCOT, Rose Corn Oil Trial; LA Vet, Los Angeles Veterans Trial; MRC-Soy, Medical Research Council 
Soybean Oil Trial; ODHS, Oslo Diet Heart Study; STARS, St Thomas Atherosclerosis Regression Study. DART, Diet and Reinfarction Trial; LA, linoleic acid; ALA, alpha-linolenic acid;  EPA, 
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Fig E. All-cause mortality in RCTs providing 
EPA+DHA) in place of SFA (main analysis)
Results are based on random-effects models.  Risk ratio
Abbreviations: MCE, Minnesota Coronary Experiment; SDHS, Sydney Diet Heart Study; R
Angeles Veterans Trial; MRC-Soy, Medical Research Council 
SFA, saturated fatty acids. 
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Fig H. CHD mortality in eight RCT
or without confounding by n-3 EPA+DHA
Abbreviations: MCE, Minnesota Coronary Experiment; SDHS, S
Angeles Veterans Trial; MRC-Soy, Medical Research Council Soy
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Meta-regression analyses explored heterogeneity in the CHD mortality HR due to between-group 
cholesterol lowering and the magnitude of the increase in LA in the intervention groups. Across the eight 
studies, every one-unit decrease in between-group cholesterol lowering was non-significantly associated 
with a 2% increase in the HR (1.02; 95% CI: 0.95, 1.10).  This model performed poorly compared with 
the model without between-group cholesterol lowering with a residual I2 of 42% and an adjusted R2 of -
107%.  Similar null findings are noted when the change in LA (%E) is examined (HR 1.02; 95% CI: 0.95, 
1.10; residual I2 42%; adjusted R2 of -76%), suggesting that neither the magnitude of serum cholesterol 
lowering nor the dose of LA help to explain the heterogeneity among the trials. 
 
Effects on composite CHD endpoints non-fatal myocardial infarction  
The traditional diet-heart hypothesis predicts that replacement of SFA with LA-rich vegetable oils will 
reduce the risk of both non-fatal and fatal CHD events, however, our meta-analysis does not include non-
fatal CHD event data. Unfortunately, several critical deficiencies in the collection and reporting of non-
fatal CHD events in these RCTs make it unfeasible to reliably estimate risk of composite CHD or non-
fatal events.  For example, one of the five RCTs in the main analysis (the SDHS) did not report non-fatal 
CHD events 113. Another RCT (the MCE) reported only a composite outcome and did not distinguish 
between soft endpoints (e.g. routine follow-up EKG suggestive of silent/asymptomatic myocardial 
infarction), and hard endpoints of acute non-fatal myocardial infarction (MI) and CHD deaths 8.   
 
Aware of these limitations, we performed exploratory sensitivity analyses of the composite endpoint (MI 
plus CHD death) and non-fatal MI alone (figs K and L, respectively).  For the MCE, we estimated non-
fatal MI by subtracting deaths attributed to "Cardiac Arrest, Heart Block" (making the assumptions that 
"Cardiac Arrest, Heart Block" is essentially comparable  to "Sudden cardiac deaths" and that all MIs were 
non-fatal).  There was no indication of benefit from the replacement of SFA with LA-rich vegetable oils 
using either composite MI plus CHD death or non-fatal MI as outcomes.  For the composite outcome of 
MI plus CHD mortality, there was a pooled hazard ratio of 1.07 (95% CI: 0.80, 1.41).  For the non-fatal MI 




Fig K. Composite endpoint (myocardial infarct
oils rich in LA (without added n-
Abbreviations: MCE, Minnesota Coronary Experiment; SDHS, Sydney Diet Heart Study; R
Angeles Veterans Trial; MRC-Soy, Medical Research Council Soybean Oil 
Diet Heart Study; STARS, St Thomas Atherosclerosis Regression Study. 
 
Fig L. Non-fatal myocardial infarcts
3 EPA+DHA) in place of SFA (sens
Abbreviations: MCE, Minnesota Coronary Experiment; SDHS, Sydney Diet Heart Study; R
Angeles Veterans Trial; MRC-Soy, Medical Research Council Soybean Oil Trial. DART, Diet and Reinfarction Trial; ODHS,
Diet Heart Study; STARS, St Thomas Atherosclerosis Regression Study. 
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Summary of Evidence 
In our main meta-analyses, based on the five RCTs that provided LA-rich vegetable oil in place of SFA, 
we found no evidence for reductions in either CHD mortality or all-cause mortality.  This conclusion was 
unchanged after sensitivity analyses that either 1) included RCTs that offered advice only or that, in 
addition to LA sources, also provided n-3 EPA and DHA, or 2) included composite or non-fatal endpoints.  
However, evidence of moderate heterogeneity weakens the conclusions we can make about the CHD 
mortality findings and their ability to translate into recommendations for the population.  Exploratory 
analyses suggest that neither the between-group differences in serum cholesterol lowering nor the doses 
of LA provided help to explain this heterogeneity.  
 
Limitations 
The small number of RCTs that have tested the traditional diet-heart hypothesis replacing SFA with LA-
rich vegetable oil is an important limitation of our meta-analysis. Remarkably, only five diet-heart RCTs 
have specifically tested whether provision of an LA-rich vegetable oil in place of SFA reduced risk of 
CHD death or all-cause mortality. The fact that the MCE accounted for about 80% of all randomized 
participants in these trials highlights the paucity of causal RCT evidence supporting the traditional diet 
heart hypothesis and the importance of the MCE in assessing the evidence base for LA-rich 
interventions. Even with inclusion of advice-only RCTs (with only modest diet changes and other 
limitations) and RCTs confounded by provision of large quantities of n-3 EPA+DHA in sensitivity 
analyses, MCE still accounted for 68% of all randomized participants. The small number of RCTs, 
coupled with differences in methodological quality and design, and population characteristics of the 
individual RCTs (tables K and L) (reviewed in 13, 109) indicate that more research is needed in this area 
before evidence-based recommendations can be supported. 
 
Conclusion 
Available RCT evidence demonstrates that replacement of SFA with LA-rich vegetable oil effectively 
lowers serum cholesterol, but does not support the hypothesis that this translates to lower risk of death 
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